Imugene Capital Raising Presentation
Filed with ASX · · 37 pages · English
Summary by 6ix AI
Imugene Ltd has released a capital raising presentation detailing plans to raise funds coinciding with new data from its azer-cel trial, which shows promising response rates in patients with lymphoma. The company aims to raise significant capital to support its clinical trials and pursue a registrational pathway with the FDA for its innovative cancer therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Imugene
- Imugene Completes $22.5M Placement and c.$15M SPP
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
- Two Additional Complete Responses in azer-cel Ph1b trial
- Notice of Extraordinary General Meeting/Proxy Form
- Azer-cel Granted FDA Fast Track Designation in Blood Cancer
Later from Imugene
- Appendix 4E and Annual Report
- Final Share Purchase Plan Allotment
- S&P DJI Announces September 2025 Quarterly Rebalance
- Strategic Collaboration with JW Therapeutics
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene